Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study

The efficacy and safety of sucroferric oxyhydroxide (SO) have been reported in clinical trials. However, real-life data are scarce. This study presents data on the use, efficacy and safety of SO in real clinical practice. We performed a retrospective multicentre study, without any influence on the p...

Full description

Saved in:
Bibliographic Details
Published in:Clinical kidney journal 2021-02, Vol.14 (2), p.681-687
Main Authors: Navarro-González, Juan F, Arenas, María Dolores, Henríquez-Palop, Fernando, Lloret, María Jesús, Molina, Pablo, Ríos Moreno, Francisco, Macia-Lagier, María Asunción, Espinel, Laura, Sánchez, Emilio, Lago, Mar, Crespo, Antonio, Bover, Jordi
Format: Article
Language:English
Subjects:
Albumin
Drugs
Ferritin
Original
Parathyroid hormone
Patient compliance
Phosphates
Prescribing
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy and safety of sucroferric oxyhydroxide (SO) have been reported in clinical trials. However, real-life data are scarce. This study presents data on the use, efficacy and safety of SO in real clinical practice. We performed a retrospective multicentre study, without any influence on the prescription decisions, that included 220 patients from 11 Spanish centres. Demographic, treatment, analytical and nutritional parameters and adherence, side effects and dropout rates were collected during 6 months. SO was initiated due to inadequate control of serum phosphate (P) in 70% of participants and in 24.5% to reduce the number of tablets. Monotherapy with SO increased from 44% to 74.1%, with a reduction in the average daily number of sachets/tablets from six to two. Serum P decreased by 20% (4.6 ± 1.2 versus 5.8 ± 1.3 mg/dL; P 
ISSN:2048-8505
2048-8513
DOI:10.1093/ckj/sfaa226